Tagged with FDA

2023: A Record Year for Cell & Gene Therapy Approvals
Sarah McMullen, Country Director, FDA India Office
2023 FDA Drug Approvals: Second Highest Count in 30 Years
The Evolution of US FDA Diversity Requirements in Clinical Research
New FDA Guidance Addresses Challenges with Cell and Gene Manufacturing Comparability and Complexity
Saudi FDA Becomes First Arab Member of PIC/S Pharma Inspection Scheme
BIO2023: FDA CBER’s Peter Marks on COVID-19 Regulatory Impact
US FDA CBER Biological License Application Approvals 2022
US FDA CDER New Drug Approvals 2022
Clinical Trial Diversity: Patient Engagement, Remote Participation & Industry Buy-In
Indian Manufacturers Still on FDA Radar as Quality Reprimands Hit Biocon and Cipla
The Future of Healthcare Is … Inclusive, Global, Individual, Digital
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here